Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance

Journal of Clinical Oncology

Volumn 21, Issue 8, 2003, Pages 1466-1471

  Bannerji, Rajat ^a   Kitada, Shinichi ^a   Flinn, Ian W ^a   Pearson, Michael ^a   Young, Donn ^a   Reed, John C ^a   Byrd, John C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; REGULATOR PROTEIN; RITUXIMAB; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; COMPLEMENT; MCL1 PROTEIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; COMPLEMENT SYSTEM PROTEINS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MULTICENTER STUDIES; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME;

EID: 0038518572     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.012     Document Type: Article

References (39)

1. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001
2. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001
3. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-3056, 2000
4. Thomas DA, O'Brien S, Giles FJ, et al: Single-agent rituxan in early stage chronic lymphocytic leukemia. Blood 98:364, 2001 (abstr)
5. Hainsworth JD, Litchy S, Burris HA, et al: Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma and chronic lymphocytic leukemia. Blood 98:363, 2001 (abstr)
6. Huhn D, von Schilling C, Wilhelm M, et al: German Chronic Lymphocytic Leukemia Study Group: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-1331, 2001
7. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-74, 2003
8. Wierda W, O'Brien S, Albitar M, et al: Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment of chronic lymphocytic leukemia. Blood 98:721, 2001 (abstr)
9. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
10. Golay J, Lazzari M, Facchinetti V, et al: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 98:3383-3389, 2001
11. Bellosillo B, Villamor N, Lopez-Guillermo A, et al: Complement-mediated cell death by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98:2271-2277, 2001
12. Pearson MD, Shinn C, Grever MR, et al: Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells (ell) independent of complement-mediated lysis but requires Fcγ receptor ligation. Blood 94:313, 1999. (abstr)
13. Pedersen IM, Buhl AM, Klausen P, et al: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99:1314-1319, 2002
14. Byrd JC, Kitada S, Flinn IW, et al: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99:1038-1043, 2002
15. Idusogie EE, Presta LG, Gazzano-Santoro H, et al: Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164:4178-4184, 2000
16. Kuraya M, Yefenof E, Klein G, et al: Expression of the complement regulatory proteins CD21, CD55, and CD59 on Burkitt lymphoma lines: Their role in sensitivity to human serum-mediated lysis. Eur J Immunol 22:1871-1876, 1992
17. Blok VT, Daha MR, Tijsma O, et al: A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 160:3437-3443, 1998
18. Brasoveanu LI, Altomonte M, Gloghini A, et al: Expression of protection (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 61:548-556, 1995
19. Harjunpaa A, Junnikkala S, Meri S: Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51:634-641, 2000
20. Golay J, Zaffaroni L, Vaccari T, et al: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908, 2000
21. Kitada S, Zapata JM, Andreeff M, et al: Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 106:995-1004, 1999
22. Robertson LE, Plunkett W, Mcconnell K, et al: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456-459, 1996
23. Aguilar-Santelises M, Rottenberg ME, Lewin N, et al: Bcl-2, Bax, and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 69:114-119, 1996
24. Thomas A, El Rouby S, Reed JC, et al: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 mutation and bcl-2/bax proteins in drug resistance. Oncogene 12:1055-1062, 1996
25. McConkey DJ, Chandra J, Wright S, et al: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of bcl-2 and bax. J Immunol 156:2624-2630, 1996
26. Kitada S, Andersen J, Akar S, et al: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with In vitro and In vivo chemoresponses. Blood 91:3379-3389, 1998
27. Sedlak TW, Oltvai ZN, Yang E, et al: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A 92:7834-7838, 1995
28. Wang K, Gross A, Waksman G, et al: Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol Cell Biol 18:6083-6089, 1998
29. Deveraux QL, Takahashi R, Salvesen GS, et al: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-304, 1997
30. Tamm I, Kornblau SM, Segall H, et al: Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796-1803, 2000
31. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
32. Byrd JC, Shinn C, Ravi R, et al: Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94:1401-1408, 1999
33. Krajewski S, Zapata JM, Reed JC: Detection of multiple antigens on western blots. Anal Biochem 236:221-228, 1996
34. Krajewski S, Bodrug S, Gascoyne R, et al: Immunohistochemical analysis of mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes. Am J Path 145:515-525, 1994
35. Iyer S, Bishop J, Abrams B, et al: QuantiBrite: A new standard for fluorescence quantitation. White paper. Becton Dickinson Immunocytometry Systems, San Jose, CA. 1997.
36. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446, 2000
37. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98:1352-1357, 2001
38. Moulding DA, Giles RV, Spiller DG, et al: Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood 96:1756-1763, 2000
39. Auer RL, Corbo M, Fegan CD, et al: Bcl-2 antisense induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells. Blood 98:808, 2001 (abstr)